Nutex Health (NASDAQ:NUTX) Shares Gap Down on Disappointing Earnings

Nutex Health Inc. (NASDAQ:NUTX) gapped down before the market opened on Friday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $105.34, but opened at $89.05. Nutex Health shares last traded at $87.46, with a volume of 229,541 shares traded.

The company reported $1.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.56 by ($3.95). The business had revenue of $151.68 million during the quarter, compared to analyst estimates of $258.82 million. Nutex Health had a net margin of 7.34% and a return on equity of 18.70%.

Trending Headlines about Nutex Health

Here are the key news stories impacting Nutex Health this week:

• Positive Sentiment: Nutex reported strong full‑year 2025 results (revenue +82% y/y to $875.3M; net income and EPS up; adjusted EBITDA +152.6%) and announced a second stock repurchase program — news that can support the stock over time by reducing share count and signaling management confidence. NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM
• Positive Sentiment: Analyst/coverage pieces are discussing valuation upside given earnings growth and the buyback, which may attract long‑term investors focused on fundamentals. Assessing Nutex Health (NUTX) Valuation After Earnings Growth And New Share Buyback Program
• Neutral Sentiment: Corporate press releases and financial filings provide the detailed numbers and management commentary — useful for investors doing due diligence but unlikely to move the market on their own. Company Press Release / Financial Report
• Negative Sentiment: Nutex’s most recent quarterly report missed expectations sharply (EPS $1.61 vs. $5.56 est.; revenue $151.7M vs. $258.8M), a short‑term catalyst for selling as it signals volatility in recent revenue drivers. MarketBeat: Earnings Summary
• Negative Sentiment: Multiple law firms (Block & Leviton, Kuehn Law and others) have launched investigations or encouraged shareholders to contact them over potential securities fraud and fiduciary‑duty claims tied to disclosure of revenue recognition and internal controls — a major overhang that raises litigation risk, potential settlements, and reputational damage. Block & Leviton Investigation Notice
• Negative Sentiment: Additional press items detail similar shareholder litigation allegations about HaloMD-related revenue recognition, internal control weaknesses, and stock‑based compensation treatment — issues that could lead to restatements or future liabilities. Kuehn Law Notice
• Negative Sentiment: Local/regional reporting highlights investor outreach from law firms, amplifying negative headlines and short‑term selling pressure. GazetteXtra: Investor Advisory

Analysts Set New Price Targets

Several research analysts have weighed in on NUTX shares. Wall Street Zen cut shares of Nutex Health from a “strong-buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings reissued a “hold (c)” rating on shares of Nutex Health in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $252.50.

Institutional Investors Weigh In On Nutex Health

A number of large investors have recently added to or reduced their stakes in NUTX. State of Alaska Department of Revenue purchased a new position in shares of Nutex Health in the 3rd quarter worth about $30,000. Islay Capital Management LLC purchased a new stake in Nutex Health in the fourth quarter worth approximately $34,000. BNP Paribas Financial Markets boosted its stake in Nutex Health by 966.7% in the second quarter. BNP Paribas Financial Markets now owns 320 shares of the company’s stock worth $40,000 after buying an additional 290 shares in the last quarter. Ameritas Investment Partners Inc. bought a new position in Nutex Health during the second quarter valued at approximately $44,000. Finally, Royal Bank of Canada grew its position in Nutex Health by 752.4% during the fourth quarter. Royal Bank of Canada now owns 358 shares of the company’s stock valued at $59,000 after acquiring an additional 316 shares during the last quarter. Hedge funds and other institutional investors own 5.32% of the company’s stock.

Nutex Health Price Performance

The stock has a market capitalization of $638.28 million, a PE ratio of 10.05 and a beta of 0.03. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.20 and a quick ratio of 3.18. The firm’s 50 day simple moving average is $136.67 and its 200 day simple moving average is $124.50.

Nutex Health Company Profile

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.